Aduro Biotech Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis...

BERKELEY, Calif., March 09, 2020 -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of.

Fly Intel: After Hours Movers ORGO CLAR SFIX ASNA MTN PRPL ADRO SNCR FLMN

President Trump says will announce major economic steps tomorrow SPX SPY

POTUS to ask Senate for payroll tax cut amid COVID-19 spread, CNBC says SPX SPY

Canaccord Genuity analyst John Newman maintained a Buy rating on Aduro BioTech (ADRO) today and set a price target of $10.00. The company's shares closed

Canaccord Genuity analyst John Newman maintained a Buy rating on Aduro BioTech (ADRO – Research Report) today and set a

AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

After a painful stretch, small-cap U.S. stocks should rebound on a few tailwinds.

Stocks Analysis by Zacks Investment Research covering: S&P 500, Microsoft Corporation, Alphabet Inc Class A, Apple Inc. Read Zacks Investment Research's latest article on Investing.com

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

Horizon Therapeutics (HZNP) beat earnings and sales estimates in the fourth quarter of 2019.

Accessory dwelling units are like the "scooters of housing policy," one expert says.

Intercept (ICPT) incurs wider loss in the fourth quarter while sales top mark. Shares fall probably as the action date for OCA's NDA to treat fibrosis due to NASH gets extended by the FDA.